OBJECTIVE: Depression is common among HIV-infected women, predicts treatment nonadherence, and consequently may impact vertical transmission of HIV. We report findings from a study evaluating preconception, pregnancy, and postpartum depressive symptoms in HIV-infected vs. at-risk, HIV-uninfected women. METHODS: We examined the prevalence and predictors of elevated perinatal (i.e., pregnancy and/or postpartum) depressive symptoms using a Center for Epidemiological Studies-Depression (CES-D) scale score of ≥16 in 139 HIV-infected and 105 HIV-uninfected women (62% African American) from the Women's Interagency HIV Study (WIHS). RESULTS: The prevalence of elevated perinatal depressive symptoms did not differ by HIV serostatus (HIV-infected 44%, HIV-uninfected 50%, p=0.44). Among HIV-infected women, the strongest predictor of elevated symptoms was preconception depression (odds ratio [OR] 5.71, 95% confidence interval [CI] 2.67-12.19, p<0.001); crack, cocaine, and/or heroin use during preconception was marginally significant (OR 3.10, 95% CI 0.96-10.01, p=0.06). In the overall sample, additional significant predictors of perinatal depression included having multiple sex partners preconception (OR 2.20, 95% CI 1.12-4.32, p=0.02), use of preconception mental health services (OR 2.51, 95% CI 1.03-6.13, p=0.04), and not graduating from high school (OR 1.92, 95% CI 1.06-3.46, p=0.03). CONCLUSIONS: Elevated perinatal depressive symptoms are common among HIV-infected and at-risk HIV-uninfected women. Depressive symptoms before pregnancy were the strongest predictor of perinatal symptoms. Findings underscore the importance of early and ongoing assessment and treatment to ensure low vertical transmission rates and improving postpregnancy outcomes for mothers and children.
OBJECTIVE:Depression is common among HIV-infectedwomen, predicts treatment nonadherence, and consequently may impact vertical transmission of HIV. We report findings from a study evaluating preconception, pregnancy, and postpartum depressive symptoms in HIV-infected vs. at-risk, HIV-uninfectedwomen. METHODS: We examined the prevalence and predictors of elevated perinatal (i.e., pregnancy and/or postpartum) depressive symptoms using a Center for Epidemiological Studies-Depression (CES-D) scale score of ≥16 in 139 HIV-infected and 105 HIV-uninfectedwomen (62% African American) from the Women's Interagency HIV Study (WIHS). RESULTS: The prevalence of elevated perinatal depressive symptoms did not differ by HIV serostatus (HIV-infected 44%, HIV-uninfected 50%, p=0.44). Among HIV-infectedwomen, the strongest predictor of elevated symptoms was preconception depression (odds ratio [OR] 5.71, 95% confidence interval [CI] 2.67-12.19, p<0.001); crack, cocaine, and/or heroin use during preconception was marginally significant (OR 3.10, 95% CI 0.96-10.01, p=0.06). In the overall sample, additional significant predictors of perinatal depression included having multiple sex partners preconception (OR 2.20, 95% CI 1.12-4.32, p=0.02), use of preconception mental health services (OR 2.51, 95% CI 1.03-6.13, p=0.04), and not graduating from high school (OR 1.92, 95% CI 1.06-3.46, p=0.03). CONCLUSIONS: Elevated perinatal depressive symptoms are common among HIV-infected and at-risk HIV-uninfectedwomen. Depressive symptoms before pregnancy were the strongest predictor of perinatal symptoms. Findings underscore the importance of early and ongoing assessment and treatment to ensure low vertical transmission rates and improving postpregnancy outcomes for mothers and children.
Authors: Judith A Cook; Mardge H Cohen; Jane Burke; Dennis Grey; Kathryn Anastos; Lynn Kirstein; Herminia Palacio; Jean Richardson; Tracey Wilson; Mary Young Journal: J Acquir Immune Defic Syndr Date: 2002-08-01 Impact factor: 3.731
Authors: Herminia Palacio; Xiuhong Li; Tracey E Wilson; Henry Sacks; Mardge H Cohen; Jean Richardson; Mary Young; Alvaro Muñoz Journal: AIDS Date: 2004-03-05 Impact factor: 4.177
Authors: Judith A Cook; Dennis Grey; Jane Burke; Mardge H Cohen; Alejandra C Gurtman; Jean L Richardson; Tracey E Wilson; Mary A Young; Nancy A Hessol Journal: Am J Public Health Date: 2004-07 Impact factor: 9.308
Authors: Nancy T Blaney; M Isabel Fernandez; Kathleen A Ethier; Tracey E Wilson; Emmanuel Walter; Linda J Koenig Journal: AIDS Patient Care STDS Date: 2004-07 Impact factor: 5.078
Authors: Bassam H Rimawi; Somer L Smith; Martina L Badell; Leilah D Zahedi-Spung; Anandi N Sheth; Lisa Haddad; Rana Chakraborty Journal: Future Virol Date: 2016-08-05 Impact factor: 1.831
Authors: Pauline M Maki; Leah H Rubin; Mardge Cohen; Elizabeth T Golub; Ruth M Greenblatt; Mary Young; Rebecca M Schwartz; Kathryn Anastos; Judith A Cook Journal: Menopause Date: 2012-11 Impact factor: 2.953
Authors: Bryna J Harrington; Brian W Pence; Mathias John; Caroline G Melhado; Jacob Phulusa; Bryan Mthiko; Bradley N Gaynes; Joanna Maselko; William C Miller; Mina C Hosseinipour Journal: J Ment Health Date: 2018-09-29
Authors: Leah H Rubin; Judith A Cook; Gayle Springer; Kathleen M Weber; Mardge H Cohen; Eileen M Martin; Victor G Valcour; Lorie Benning; Christine Alden; Joel Milam; Kathryn Anastos; Mary A Young; Deborah R Gustafson; Erin E Sundermann; Pauline M Maki Journal: AIDS Date: 2017-08-28 Impact factor: 4.177